Previous 10 | Next 10 |
U.S. Food Drug Administration approved CARVYKTI ™ (ciltacabtagene autoleucel; cilta-cel), a BCMA-directed CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have received four or more prior lines of therapy, including a pr...
Despite recent regulatory hurdles, the U.S.-listed Chinese pharmaceutical companies have made a comeback in the morning hours on Wednesday. Notable gainers include I-Mab (IMAB +17.9%), BeiGene (BGNE +20.8%), Legend Biotech (LEGN +9.3%), Zai Lab (ZLAB +30.4%), HUTCHMED < > Limited (HCM...
Concord, Mass.-based Adiso Therapeutics, an anti-inflammatory biotech, officially emerged from stealth mode with backing from Hong Kong's Morningside Ventures. Morningside has already invested $60 million in the company and has another $35 million earmarked for the company's B round. ...
The clinical-stage biopharmaceutical company, Legend Biotech (NASDAQ:LEGN), announced on Monday an Interim Product Supply Agreement with Janssen Biotech of Johnson & Johnson (NYSE:JNJ) for recently approved CAR-T therapy, ciltacabtagene autoleucel (cilta-cel). The deal, which is connected...
Suzhou antibody company Adagene will apply its masking technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentia...
So far, 2022 has been an ugly year for a lot of stocks. But if you look out over the next five years, you can find some amazing opportunities. Our roundtable of three Motley Fool contributors has found three biotech stocks that might be 11-baggers in five years. Patrick Bafuma is bullis...
Legend Biotech's IPO was among the Top five largest of 2020. Compared to the other four, Legend's share price has performed exceptionally well. Legend partnered with JNJ drug development subsidiary Janssen on its lead candidate cilta-cel, now called Carvykti, and approved last week in...
The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson (NYSE:JNJ) and Legend Biotech's (NASDAQ:LEGN) CAR-T therapy Carvykti to treat adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhib...
The company expects to lose up to $519 million last year, but its fortunes may improve after its Legend Biotech unit received FDA approval this week for a new CAR-T cell therapy product. Genscript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounti...
CARVYKTI™ marks the first product approved by a health authority for Legend Biotech Approval is primarily based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with refractory or relapsed multipl...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...